Efficacy and Safety of the Biosimilar ABP 215 Compared with Bevacizumab in Patients with Advanced Nonsquamous Non-small Cell Lung Cancer (MAPLE): A Randomized, Double-blind, Phase III Study.

Nicholas ThatcherJerome H GoldschmidtMichael ThomasMichael SchenkerZhiying PanLuis Paz-Ares RodriguezValeriy BrederGyula OstorosVladimir Hanes

Published in: Clinical cancer research : an official journal of the American Association for Cancer Research (2019)

ABP 215 is similar to bevacizumab RP with respect to clinical efficacy, safety, immunogenicity, and pharmacokinetics. The totality of evidence supports clinical equivalence of ABP 215 and bevacizumab.

Keyphrases

phase iii
double blind
metastatic colorectal cancer
clinical trial
placebo controlled
open label
phase ii
study protocol